| Funding Opportunity ID: | 333155 | | Opportunity Number: | RFA-NS-21-022 | | Opportunity Title: | Translational Neural Devices (U44 Clinical Trial Optional) | | Opportunity Category: | Discretionary | | Opportunity Category Explanation: | | | Funding Instrument Type: | Cooperative Agreement | | Category of Funding Activity: | Health | | Category Explanation: | | | CFDA Number(s): | 93.853 | | Eligible Applicants: | Small businesses | | Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. | | Agency Code: | HHS-NIH11 | | Agency Name: | Department of Health and Human Services
National Institutes of Health | | Posted Date: | Apr 28, 2021 | | Close Date: | Feb 20, 2024 | | Last Updated Date: | Apr 28, 2021 | | Award Ceiling: | $1,000,000 | | Award Floor: | $0 | | Estimated Total Program Funding: | $4,000,000 | | Expected Number of Awards: | | | Description: | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design. | | Version: | 1 |
|
